search
Back to results

Evaluation of Endoscopic Submucosal Dissection (ESD) Efficacy (DISSECMUC)

Primary Purpose

Colorectal Neoplasms, Endoscopic Submucosal Dissection

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Endoscopic submucosal dissection (ESD)
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Colorectal Neoplasms focused on measuring Colorectal Neoplasms

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with superficial medium or distal rectal tumors more than 1 cm in size
  • Criteria for ESD were determined by the endoscopic characteristics and histological findings of biopsy specimens
  • Endoscopic ultrasonography (EUS) also was performed when the lesion was strongly suspected of submucosal invasion.
  • Age older than 18, younger than 85 years.

Exclusion Criteria:

  • Lesion less than 10 mm in size
  • Pedundulated lesion
  • Suspicion of submucosal invasion (MRI or EUS)
  • Distant metastasis on CTscan
  • Coagulopathy
  • Pregnancy
  • Refusal to participate to the study or inability to consent

Sites / Locations

  • Gastroenterology Unit, European Georges Pompidou Hospital, Assistance Publique - Hôpitaux de Paris

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Endoscopic submucosal dissection (ESD)

Arm Description

Endoscopic submucosal dissection (ESD)

Outcomes

Primary Outcome Measures

curative resection rate (3 month)
Evaluate the curative R0 resection rate at 3 months without surgical therapy, in patients with superficial rectal tumours

Secondary Outcome Measures

monobloc resection rate
evaluate the monobloc resection rate
complication rate
evaluate the complication rate
complete resection predictive factors
evaluate the complete resection predictive factors
Curative resection rate (1 year)
Evaluate the curative R0 resection rate at 1 year without surgical therapy, in patients with superficial rectal tumours

Full Information

First Posted
June 12, 2013
Last Updated
September 17, 2013
Sponsor
Assistance Publique - Hôpitaux de Paris
search

1. Study Identification

Unique Protocol Identification Number
NCT01879904
Brief Title
Evaluation of Endoscopic Submucosal Dissection (ESD) Efficacy
Acronym
DISSECMUC
Official Title
Evaluation of Endoscopic Submucosal Dissection (ESD) Efficacy
Study Type
Interventional

2. Study Status

Record Verification Date
June 2013
Overall Recruitment Status
Completed
Study Start Date
February 2010 (undefined)
Primary Completion Date
July 2013 (Actual)
Study Completion Date
July 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Superficial rectal tumors could be removed by ESD with two major advantages showed by the literature: high rate of monobloc resection and R0 resection. Hence, recurrence rate was lower than ERM therapy. This technique is actually performed routinely in Japan and experience is limited in Europe, with few data in the literature. This study is suggested to patients with superficial medium or distal rectal tumors. The lesion was identified and demarcated using white-light endoscopy, magnifying endoscopy, and chromoendoscopy. Then, marking around the lesions was performed. Local injection was made using injection needle, and then mucosal incision was performed around the lesion using endo-knives. Submucosal dissection was performed using endo-knives. Hemostasis and vessel coagulation were practiced using primary hemostatic forceps during the procedure. Follow-up is one year. For lesion with invasive carcinoma (vessel and lymphatic involvement, undifferentiated, free margin less than 1 mm), a surgical resection is performed. All the patients have an endoscopic control 3 months after ESD (rectosigmoidoscopy with biopsies): For complete resection, an endoscopic control was performed at 1 year. For incomplete resection, another endoscopic therapy was attempted (EMR) an endoscopic control was performed at 1 year. At one year, patient with incomplete resection have a surgical resection.
Detailed Description
Colorectal neoplasia prevalence was 35 000 for a total number of 278 000 cancers in France during 2000. Treatment of these cancers is based on local extension especially in the digestive tract (stade) and on co-morbidities of the patient. There are many advantages to treat these cancers at an early stade (involving mucosa or superficial submucosa), since they are associated with a better prognosis with a lower cost-effectivness ratio. Indeed, in 2003 mean cost of treatment of colorectal cancer during the first year following diagnosis was 24 000 €, whereas it was only 18 000 € for early stade and up to 36 000 € for the most advanced stade. Transversal (1 week) and national survey of the French society of endoscopy (SFED) during 8 years demonstrated that among 1 millions of endoscopies (3/4 being performed with anesthesia), 8000 were performed for endosocpic treatment of early digestive cancers by endoscopic mucosal resection (EMR) or more recently by endoscopic submucosal dissection (ESD). One of the problems to diffuse these endoscopic treatments is the multiple tools required to endotherapy, and the fact that this treatment is time-consuming, whereas a simple ablation of polyps (polypectomy) smaller than 1.5 cm needs only 5 to 10 minutes. For exemple, endotherapeutic tools for polypectomy (one needle and one polypectomy loop) costs 180 € and occasionally required a couple of clips when rare (1%) hemorrhage or exceptional (1p1000) perforation occurred. Conversely, endotherapy tools for ESD of early mucosal or submucosal digestive cancers larger than 1.5 cm up to 4-5 cm, costs 1500 €, including needles, submucosal injected products, hook-knife, insulinated-knife and coagulation rasper. So, the recent T2A codification gathers these two kinds of endoscopic treatment under the same code, whatever the size of the lesion, whereas costs of tools required for their treatment are notably different especially when there are performed for inpatients hospitalized less that 2 days which is only charged 480 € added of 192 € and 53€ for salary in private exercise or 914 € in public hospital, by the national and public healthcare system. Beside the expertise required for EMR and ESD of larger early cancers, this cost does not invite to increase the frequency of EMR or ESD, taking into account that this treatment is better practised by two simultaneous endoscopists, one of them manipulating the endoscope en endotherapy tools.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colorectal Neoplasms, Endoscopic Submucosal Dissection
Keywords
Colorectal Neoplasms

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
48 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Endoscopic submucosal dissection (ESD)
Arm Type
Experimental
Arm Description
Endoscopic submucosal dissection (ESD)
Intervention Type
Procedure
Intervention Name(s)
Endoscopic submucosal dissection (ESD)
Other Intervention Name(s)
endoscopic submucosal dissection
Intervention Description
This study is suggest to patients with superficial medium or distal rectal tumors. The lesion was identified and demarcated using white-light endoscopy, magnifying endoscopy, and chromoendoscopy. Then, marking around the lesions was performed. Local injection was made using injection needle, and then mucosal incision was performed around the lesion using endo-knives. Submucosal dissection was performed using endo-knives. Hemostasis and vessel coagulation were practiced using primary hemostatic forceps during the procedure.
Primary Outcome Measure Information:
Title
curative resection rate (3 month)
Description
Evaluate the curative R0 resection rate at 3 months without surgical therapy, in patients with superficial rectal tumours
Time Frame
3 months
Secondary Outcome Measure Information:
Title
monobloc resection rate
Description
evaluate the monobloc resection rate
Time Frame
1 year
Title
complication rate
Description
evaluate the complication rate
Time Frame
1 year
Title
complete resection predictive factors
Description
evaluate the complete resection predictive factors
Time Frame
1 year
Title
Curative resection rate (1 year)
Description
Evaluate the curative R0 resection rate at 1 year without surgical therapy, in patients with superficial rectal tumours
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with superficial medium or distal rectal tumors more than 1 cm in size Criteria for ESD were determined by the endoscopic characteristics and histological findings of biopsy specimens Endoscopic ultrasonography (EUS) also was performed when the lesion was strongly suspected of submucosal invasion. Age older than 18, younger than 85 years. Exclusion Criteria: Lesion less than 10 mm in size Pedundulated lesion Suspicion of submucosal invasion (MRI or EUS) Distant metastasis on CTscan Coagulopathy Pregnancy Refusal to participate to the study or inability to consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christophe Cellier, PD, PhD
Organizational Affiliation
Hôpital Européen Georges-Pompidou
Official's Role
Principal Investigator
Facility Information:
Facility Name
Gastroenterology Unit, European Georges Pompidou Hospital, Assistance Publique - Hôpitaux de Paris
City
Paris
ZIP/Postal Code
75015
Country
France

12. IPD Sharing Statement

Learn more about this trial

Evaluation of Endoscopic Submucosal Dissection (ESD) Efficacy

We'll reach out to this number within 24 hrs